Immune phenotype in children with therapy-naïve remitted and relapsed Crohn's disease

Aron Cseh1, Barna Vasarhelyi, Kriszta Molnar

  • 1Research Group for Pediatrics and Nephrology, Semmelweis University and Hungarian Academy of Sciences, H-1083, Budapest, Hungary. cseharon@gmail.com

Insights

Pediatric Crohn's disease (CD) shows altered immune cell populations, particularly T cells and dendritic cells (DCs). Immune cell abnormalities in children with CD improve with disease remission, suggesting a link between immune status and disease activity.

Area of Science:

  • Immunology
  • Pediatric Gastroenterology

Background:

  • Childhood Crohn's disease (CD) involves complex immune dysregulation.
  • Understanding immune cell dynamics in pediatric CD is crucial for effective treatment.

Purpose of the Study:

  • To characterize immune cell subpopulations in therapy-naïve pediatric CD.
  • To assess if immune phenotype normalizes with clinical remission in childhood CD.

Main Methods:

  • Studied 26 pediatric CD patients (naïve, relapsed, remitted) and 15 controls.
  • Analyzed T cell subsets (Th1, Th2, naïve, memory, regulatory), NK cells, dendritic cells (DCs), and monocytes.
  • Assessed Toll-like receptor (TLR)-2 and TLR-4 expression on DCs and monocytes.

Main Results:

  • Therapy-naïve and relapsed CD showed decreased Th1 cells and increased memory/activated lymphocytes, DCs, and monocytes.
  • Elevated myeloid/plasmacytoid DC ratios and higher TLR-2/TLR-4 expression on DCs/monocytes were observed in naïve CD.
  • Most immune alterations normalized in remitted CD patients.

Conclusions:

  • Immune phenotype normalization in remission suggests a link to disease activity in pediatric CD.
  • Both adaptive and innate immune systems are implicated in childhood CD pathogenesis.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...